• Benjamin S Maxey, John W Pruitt, Ashley Deville, Carver Montgomery, Alan D Kaye, and Ivan Urits.
• School of Medicine, Louisiana State University Health Science Center Shreveport, Shreveport, LA, USA. bsm005@lsuhs.edu.
• Curr Pain Headache Rep. 2022 Apr 1; 26 (4): 337-346.

Purpose Of ReviewThis paper will examine the efficacy and safety of occipital nerve stimulation as a non-pharmacological alternative treatment for migraine.Recent FindingsMigraine is characterized as a primary headache disorder with possible premonitory and aura phases, both of which vary greatly in symptomatology. The most common treatments for chronic migraine are pharmacological and are aimed at both acute relief (e.g., nonsteroidal anti-inflammatory drugs, triptans, and ergots) and prophylaxis (e.g., propranolol, valproic acid, and topiramate). For patients with medically refractory migraine, acute relief medication overuse can increase the risk of developing more severe and more frequent migraine attacks. Occipital nerve stimulation is a non-pharmacological alternative treatment for chronic migraine, which could eliminate the risk of adverse effects from acute relief medication overuse. Neurostimulation is thought to prevent pain by blocking signal transduction from small nociceptive fibers with non-painful signaling in larger adjacent fibers. Existing data from clinical trials support the overall safety and efficacy of occipital nerve stimulation for the treatment of chronic migraine. However, few large controlled, double-blinded studies have been conducted, due to both practical and ethical concerns. Currently, occipital nerve stimulation is available as an off-label use of neurostimulation for pain prevention but is not approved by the FDA specifically for the treatment of chronic migraine.© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

12 keywords...

hide…